ROCKVILLE, MD, June 11, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conference this month:
Goldman Sachs 45th Annual Global Healthcare Conference (Miami Beach). MacroGenics’ President & Chief Executive Officer, Scott Koenig, M.D., Ph.D., will provide a corporate presentation on Thursday, June 13, 2024, at 10:00am ET. MacroGenics’ management will also participate in one-on-one meetings.
A webcast of the above presentation may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics' website at The Company will maintain an archived replay of this webcast on its website for 30 days after the conference.
About MacroGenics, Inc.MacroGenics (the Company) is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.
###
CONTACTS: Jim Karrels, Senior Vice President, CFO 1-301-251-5172, info@macrogenics.com
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.